| Date | Title | Description |
| 03.03.2026 | Diversity will define the next era of biotech infrastructure | - |
| 26.01.2026 | [Opinion] 2026: The Dawn of AI-Driven Drug Development | (Yicai) Jan. 23 -- The next big leap for artificial intelligence in healthcare is no longer in the lab, but in clinical trials -- where drug development succeeds or fails.
For years, the conversation around AI in healthcare has been dominat... |
| 21.01.2026 | This biotech stock has plummeted over the past year. RBC sees big turnaround ahead | - |
| 19.12.2025 | The rise and impact of AI in Biotechnology and Healthcare | - |
| 17.12.2025 | Valinor: $13 Million Seed Funding Raised To Boost Clinical Trial Success With Multimodal Machine Learning | Valinor, a San Francisco-based AI company focused on improving clinical trial outcomes through machine-learning-driven patient response prediction, announced $13 million in seed funding to scale its multimodal platform for patient selection... |
| 16.12.2025 | Valinor Secures $13 Million to Revolutionize Clinical Trials with AI | Valinor, a San Francisco-based AI firm, just raised $13 million. This seed funding aims to improve clinical trial success. The company uses machine learning. It analyzes patient data to predict treatment response. This reduces trial failure... |
| 13.12.2025 | Valinor Raises $13 Million To Advance AI-Driven Patient Selection For Clinical Trials | Valinor, a San Francisco-based artificial intelligence company focused on improving clinical trial outcomes, has raised $13 million in seed funding to expand its proprietary machine learning platform for patient selection. The financing was... |
| 01.12.2025 | Ship fast, optimize later: top AI engineers don't care about cost — they're prioritizing deployment | Across industries, rising compute expenses are often cited as a barrier to AI adoption — but leading companies are finding that cost is no longer the real constraint. The tougher challenges (and the ones top of mind for many tech leaders)? ... |
| 18.11.2025 | SOFR Academy Adds Chávez; Stocks Mixed Amid AI Doubts | SOFR Academy hires R. Martin Chávez. He's a financial tech expert. Stocks are mixed. AMD gains on AI hopes. Doubts linger about AI stock valuations.
Stocks showed mixed performance. The S&P 500 saw a slight dip. The Dow Jones Industrial... |
| 12.11.2025 | SOFR Academy Appoints R. Martin “Marty” Chávez as Senior Advisor | SOFR Academy, Inc., a leading financial engineering firm, today announced the appointment of R. Martin “Marty” Chávez as Senior Advisor. Widely regarded as one of the most influential figures at the intersection of finance, technology, and ... |
| 02.09.2025 | AI-driven drug discovery picks up as FDA pushes to reduce animal testing | Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near future.
Within the next three to five years, using ... |
| 18.05.2025 | Somite AI: $47 Million Series A Raised To Accelerate Human Cell Therapy Development | Somite AI, a tech-bio company utilizing foundation models and proprietary AI to advance human cell therapy development, announced it closed a Series A funding round raising more than $47 million. The funding round was led by Khosla Ventures... |
| 18.03.2025 | The AI Revolution: Transforming Storage and Communication | In the world of technology, change is the only constant. The latest advancements in artificial intelligence (AI) are reshaping how businesses operate. Two recent announcements from MinIO and Zoom highlight this transformation. They showcase... |
| 17.03.2025 | MinIO Deepens Support for the NVIDIA AI Ecosystem | New MinIO AIStor integrations leverage NVIDIA’s emerging infrastructure technologies and capabilities to rapidly deliver unparalleled innovation in AI storage at the multi-exabyte scale
To further support the demands of modern AI workloads,... |
| 17.03.2025 | MinIO Deepens Support for the NVIDIA AI Ecosystem | New MinIO AIStor integrations leverage NVIDIA's emerging infrastructure technologies and capabilities to rapidly deliver unparalleled innovation in AI storage at the multi-exabyte scale
REDWOOD CITY, Calif., March 17, 2025 /PRNewswire/ -- T... |
| 03.03.2025 | Altitude Lab: Incubated Startups Raised $154 Million In Capital | Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Created by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing f... |
| 23.10.2024 | Berlin-based Dunia.ai raises €10.6 million to accelerate clean energy innovations | Dunia, a pioneering force in AI-driven material discovery, today announced it has secured €10.6 million in funding co-led by Elaia and redalpine. Other backers include the EIC, Pace Ventures, Kindred Capital, Deep Science Ventures, and Angl... |
| 21.09.2024 | University Of Utah And EPIC Ventures Partner Collaborating On Investment Arm | The University of Utah (one of the nation’s leading research universities) and EPIC Ventures (a Salt Lake City based early-stage VC firm) have partnered to launch University of Utah Ventures, Powered by EPIC. And by combining the U’s innova... |
| 16.09.2024 | Circle Pharma Expands Leadership Team to Drive the Development of Its Pipeline of Oral Macrocycle Therapies | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–September 16, 2024–
Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced ... |
| 01.09.2024 | Noetik: AI-Based Biotech Company Raises $40 Million (Series A) To Develop Cancer Therapeutics | Noetik – an AI-based biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics – announced that it closed an oversubscribed $40 million Series A financing rou... |
| 20.12.2023 | Biotech breakthroughs: Stocks that soared from medical innovations | On the heels of the devastating COVID-19 pandemic, investor enthusiasm for biotech stocks waned as the Federal Reserve embarked on its aggressive rate-hiking campaign to bring down the red-hot inflation that ensued.
As companies grappled w... |
| 29.11.2023 | Cradle raises $24m for GenAI biotech platform | |
| 29.08.2023 | ИИ помогает в поиске лекарств. Они поступят в продажу раньше, чем кажется | В феврале 2020 года команда исследователей из Массачусетского технологического института использовала искусственный интеллект для поиска средства, способного уничтожить кишечную палочку и устойчивый к антибиотикам штамм бактериальной инфекц... |
| 31.07.2023 | 4 Ways Biopharma Is Applying AI/ML to Improve Drug Development Outcomes | Healthcare innovation in drug development intersects with a few critical trends: the rise of artificial intelligence (AI) applications in healthcare—particularly machine learning (ML) and predictive analytics; the need to reduce the costs a... |
| 29.07.2023 | In AI-enabled drug discovery, there might be more than one winner | W
elcome to the TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+ column where it gets its name. Want it in your inbox every Saturday? Sign up here.
Today, a look at Israel from three diff... |
| 12.07.2023 | Nvidia invests $50 million in biotech startup Recursion to train AI models for drug discovery | Back in June, we wrote about Nvidia after the chipmaker, along with other tech giants poured $1.3 billion into Inflection, an AI startup founded by LinkedIn and DeepMind co-founders.
Now, with Nvidia boasting a staggering market capitaliza... |
| 12.07.2023 | Recursion Stock Soars After Nvidia Invests $50 Million for AI Drug Discovery | Recursion Pharmaceuticals announced on Wednesday that it has received a $50 million investment from Nvidia through a private investment in public equity, or PIPE, transaction. |
| 21.06.2023 | Sanofi Goes All-In On AI | Chief Executive Officer of French pharmaceutical giant Sanofi, Paul Hudson, Paris, September 8, ... [+] 2021. (Photo by JOEL SAGET / AFP) (Photo by JOEL SAGET/AFP via Getty Images)AFP via Getty Images |
| 27.02.2023 | Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results | Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readouts
Delivered against core elements of our Roche-Genentech collaboration (neuroscience and an indication in ... |
| 25.01.2023 | The CEO of a $1.6 billion biotech says his bet on AI is paying off with faster, cheaper research that could reshape the industry | Recursion Pharmaceuticals' lab in Salt Lake City. Recursion Pharmaceuticals This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Recursion is hosting about 60 investors and analysts at its hea... |
| 02.03.2022 | Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022 | “AI will continue to have a demonstrable impact on human health. Having spent the last three years ideating with my fellow charter members to establish AAIH, I’m honored to take the reins and thrilled I get to engage with an incredible team... |
| 25.02.2022 | First Wholly AI-Developed Drug Enters Phase 1 Trials | Drug development is increasingly turning to AI Gavriil Grigorov/TASS |
| 08.02.2022 | Recursion to Participate in Upcoming Investor Conferences | SALT LAKE CITY, Feb. 8, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor confere... |
| 29.12.2021 | What will applied AI look like in 2022? | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
AI adoption has skyrocketed throughout the last 1... |
| 29.12.2021 | What will applied AI look like in 2022? | Hear from CIOs, CTOs, and other C-level and senior execs on data and AI strategies at the Future of Work Summit this January 12, 2022. Learn more
AI adoption has skyrocketed throughout the last 18 months. Besides Joe McKendrick, who wrote t... |
| 07.12.2021 | Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Method... | SALT LAKE CITY, Dec. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovatio... |
| 06.12.2021 | Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities | SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovatio... |
| 30.11.2021 | Recursion Enhances its Leadership Team and Deepens Focus on Neuroscience with Three Senior Appointments | SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovati... |
| 11.09.2021 | Как алгоритмы распознавания лиц помогут в лечении сотен заболеваний | Вычислительный биолог Анна Карпентер разработала первый алгоритм профилирования клеток на основе полученных с микроскопа изображений. Сегодня такие алгоритмы, в основе которых лежит технология распознавания лиц для социальных сетей, помогаю... |
| 13.07.2021 | Recursion Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD | |
| 13.07.2021 | Recursion : Announces Therapeutics Advisory Board, Chaired by Joseph Miletich, MD, PhD | SALT LAKE CITY, July 13, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering... |
| 23.06.2021 | Recursion : Announces Multi-Year Collaboration with Mila for Tech-Enabled Drug Discovery | Recursion to open office space within Mila and build machine learning team to focus on some of drug discovery's most challenging problems
MONTRÉAL, June 23, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology compa... |
| 15.06.2021 | Recursion Announces its First Major Multidisciplinary Expansion, in Toronto, to Further Tech-Enabled Drug Discovery | |
| 08.06.2021 | Altitude Lab Launches Investor Coalition to Fund and Mentor Healthcare Startups in Utah | |
| 25.05.2021 | Recursion Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis | |
| 25.05.2021 | RECURSION PHARMACEUTICALS, INC.
Recursion Pharmaceuticals : Announces First Internally-Developed NCE Advanced to IND-Enabling Studies to Potentially Treat Clostridium difficile Colitis | SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine le... |
| 12.05.2021 | RECURSION PHARMACEUTICALS, INC.
Recursion Pharmaceuticals : Reports First Quarter 2021 Financials and Provides Business Updates | SALT LAKE CITY, May 12, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data scien... |
| 12.05.2021 | Recursion Reports First Quarter 2021 Financials and Provides Business Updates | |
| 21.04.2021 | Recursion Pharmaceuticals Announces Closing of Initial Public Offering | |
| 21.04.2021 | RECURSION PHARMACEUTICALS, INC.
Recursion Pharmaceuticals : Announces Closing of Initial Public Offering | SALT LAKE CITY, April 21, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock... |
| 16.04.2021 | Recursion Pharmaceuticals Announces Pricing of Initial Public Offering | |
| 16.04.2021 | RECURSION PHARMACEUTICALS, INC.
Recursion Pharmaceuticals : Announces Pricing of Initial Public Offering | SALT LAKE CITY, April 16, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.... |
| 01.03.2021 | R. Martin Chavez Appointed Chairman of Recursion's Board of Directors | SALT LAKE CITY, March 1, 2021 /PRNewswire/ -- Recursion, a digital biology company industrializing drug discovery, today announced the appointment of R. Martin Chavez as Chairman of its Board of Directors. Dr. Chavez, who joined Recursion's... |
| - | Nvidia invests $50 million in biotech company Recursion for A.I. drug discovery | Chipmaker Nvidia will invest $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm’s artificial intelligence models for drug discovery.
Salt Lake City, Utah-based Recursion will use its biological and chem... |
| - |
Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly | Monday - Friday, 6:00 - 7:00 PM ET
In a Friday interview with CNBC’s Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine learning to create new drugs.
Recursion Pharm... |
| - | Nvidia holdings disclosure pumps up shares of small AI companies | A filing by Nvidia shows the chipmaker has stakes in a handful of public companies.
Shares of most of those companies soared even though Nvidia’s involvement was already known.
While Nvidia has long been involved with venture investing, its... |
